Advertisement
Screener

Exelixis Inc (EXEL) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Exelixis Inc Operating Cash Flow

Exelixis Inc (EXEL) reported Operating Cash Flow of $559.59 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05

  • Exelixis Inc net cash provided by (used in) operating activities for the quarter ending 2026-07-03 was $307.74M, a 528.13% increase year-over-year.
  • Exelixis Inc net cash provided by (used in) operating activities for the quarter ending 2026-04-03 was $251.84M, a 19.11% increase year-over-year.
  • Exelixis Inc net cash provided by (used in) operating activities for the quarter ending 2026-01-02 was $333.51M, a 38.81% increase year-over-year.
  • Exelixis Inc net cash provided by (used in) operating activities for the quarter ending 2025-10-03 was $290.32M, a 7.00% increase year-over-year.
  • Exelixis Inc net cash provided by (used in) operating activities for fiscal 2026 was $884.27M, a 26.33% increase from fiscal 2025.
  • Exelixis Inc net cash provided by (used in) operating activities for fiscal 2025 was $699.97M, a 110.00% increase from fiscal 2023.
  • Exelixis Inc net cash provided by (used in) operating activities for fiscal 2023 was $333.32M, a 8.08% decline from fiscal 2022.
  • Exelixis Inc net cash provided by (used in) operating activities for fiscal 2022 was $362.61M, a 9.53% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 month
2026-07-03$307.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$559.59M
10-Q · filed 2026-08-05
$893.10M
derived: sum of 3 quarters · filed 2026-08-05
$1.18B
derived: sum of 4 quarters · filed 2026-08-05
2026-04-03$251.84M
10-Q · filed 2026-05-05
$585.36M
derived: sum of 2 quarters · filed 2026-05-05
$875.68M
derived: sum of 3 quarters · filed 2026-05-05
$924.67M
derived: sum of 4 quarters · filed 2026-08-05
2026-01-02$333.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
$623.84M
derived: sum of 2 quarters · filed 2026-02-10
$672.83M
derived: sum of 3 quarters · filed 2026-08-05
$884.27M
10-K · filed 2026-02-10
2025-10-03$290.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$339.31M
derived: sum of 2 quarters · filed 2026-08-05
$550.75M
10-Q · filed 2025-11-04
$791.01M
derived: sum of 4 quarters · filed 2026-08-05
2025-07-04$48.99M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$260.43M
10-Q · filed 2026-08-05
$500.69M
derived: sum of 3 quarters · filed 2026-08-05
$772.03M
derived: sum of 4 quarters · filed 2026-08-05
2025-04-04$211.44M
10-Q · filed 2026-05-05
$451.70M
derived: sum of 2 quarters · filed 2026-05-05
$723.04M
derived: sum of 3 quarters · filed 2026-05-05
$842.59M
derived: sum of 4 quarters · filed 2026-05-05
2025-01-03$240.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
$511.60M
derived: sum of 2 quarters · filed 2026-02-10
$631.15M
derived: sum of 3 quarters · filed 2026-02-10
$699.97M
10-K · filed 2026-02-10
2024-09-27$271.34M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$390.89M
derived: sum of 2 quarters · filed 2025-11-04
$459.71M
10-Q · filed 2025-11-04
$470.28M
derived: sum of 4 quarters · filed 2026-02-10
2024-06-28$119.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28
$188.37M
10-Q · filed 2025-07-28
$198.94M
derived: sum of 3 quarters · filed 2026-02-10
$316.31M
derived: sum of 4 quarters · filed 2026-02-10
2024-03-29$68.82M
10-Q · filed 2025-05-13
$79.39M
derived: sum of 2 quarters · filed 2026-02-10
$196.76M
derived: sum of 3 quarters · filed 2026-02-10
$317.74M
derived: sum of 4 quarters · filed 2026-02-10
2023-12-29$10.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10
$127.94M
derived: sum of 2 quarters · filed 2026-02-10
$248.92M
derived: sum of 3 quarters · filed 2026-02-10
$333.32M
10-K · filed 2026-02-10
2023-09-29$117.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29
$238.34M
derived: sum of 2 quarters · filed 2024-10-29
$322.75M
10-Q · filed 2024-10-29
$396.45M
derived: sum of 4 quarters · filed 2025-02-11
2023-06-30$120.98M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$205.39M
10-Q · filed 2024-08-06
$279.08M
derived: sum of 3 quarters · filed 2025-02-11
$389.15M
derived: sum of 4 quarters · filed 2025-02-11
2023-03-31$84.41M
10-Q · filed 2024-04-30
$158.10M
derived: sum of 2 quarters · filed 2025-02-11
$268.17M
derived: sum of 3 quarters · filed 2025-02-11
$299.30M
derived: sum of 4 quarters · filed 2025-02-11
2022-12-30$73.69M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11
$183.76M
derived: sum of 2 quarters · filed 2025-02-11
$214.90M
derived: sum of 3 quarters · filed 2025-02-11
$362.61M
10-K · filed 2025-02-11
2022-09-30$110.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
$141.20M
derived: sum of 2 quarters · filed 2023-11-01
$288.92M
10-Q · filed 2023-11-01
$385.37M
derived: sum of 4 quarters · filed 2024-02-06
2022-07-01$31.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01
$178.85M
10-Q · filed 2023-08-01
$275.30M
derived: sum of 3 quarters · filed 2024-02-06
$358.61M
derived: sum of 4 quarters · filed 2024-02-06
2022-04-01$147.72M
10-Q · filed 2023-05-09
$244.17M
derived: sum of 2 quarters · filed 2024-02-06
$327.48M
derived: sum of 3 quarters · filed 2024-02-06
$508.98M
derived: sum of 4 quarters · filed 2024-02-06
2021-12-31$96.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06
$179.76M
derived: sum of 2 quarters · filed 2024-02-06
$361.26M
derived: sum of 3 quarters · filed 2024-02-06
$400.80M
10-K · filed 2024-02-06
2021-10-01$83.31M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$264.81M
derived: sum of 2 quarters · filed 2022-11-01
$304.35M
10-Q · filed 2022-11-01
$337.64M
derived: sum of 4 quarters · filed 2023-02-07
2021-07-02$181.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$221.04M
10-Q · filed 2022-08-09
$254.34M
derived: sum of 3 quarters · filed 2023-02-07
$272.28M
derived: sum of 4 quarters · filed 2023-02-07
2021-04-02$39.54M
10-Q · filed 2022-05-10
$72.84M
derived: sum of 2 quarters · filed 2023-02-07
$90.78M
derived: sum of 3 quarters · filed 2023-02-07
$192.45M
derived: sum of 4 quarters · filed 2023-02-07
2021-01-01$33.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07
$51.23M
derived: sum of 2 quarters · filed 2023-02-07
$152.91M
derived: sum of 3 quarters · filed 2023-02-07
$208.98M
10-K · filed 2023-02-07
2020-10-02$17.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
$119.61M
derived: sum of 2 quarters · filed 2021-11-02
$175.69M
10-Q · filed 2021-11-02
$333.71M
derived: sum of 4 quarters · filed 2022-02-18
2020-07-03$101.68M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$157.75M
10-Q · filed 2021-08-05
$315.77M
derived: sum of 3 quarters · filed 2022-02-18
$391.39M
derived: sum of 4 quarters · filed 2022-02-18
2020-04-03$56.07M
10-Q · filed 2021-05-06
$214.09M
derived: sum of 2 quarters · filed 2022-02-18
$289.71M
derived: sum of 3 quarters · filed 2022-02-18
$421.44M
derived: sum of 4 quarters · filed 2022-02-18
2020-01-03$158.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18
$233.63M
derived: sum of 2 quarters · filed 2022-02-18
$365.36M
derived: sum of 3 quarters · filed 2022-02-18
$526.96M
10-K · filed 2022-02-18
2019-09-27$75.61M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$207.34M
derived: sum of 2 quarters · filed 2020-11-05
$368.94M
10-Q · filed 2020-11-05
$473.53M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-28$131.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$293.32M
10-Q · filed 2020-08-06
$397.91M
derived: sum of 3 quarters · filed 2020-08-06
$562.77M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-29$161.59M
10-Q · filed 2020-05-05
$266.18M
derived: sum of 2 quarters · filed 2020-05-05
$431.04M
derived: sum of 3 quarters · filed 2020-05-05
$505.50M
derived: sum of 4 quarters · filed 2020-05-05
2018-12-28$104.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$269.45M
derived: sum of 2 quarters · filed 2020-02-25
$343.91M
derived: sum of 3 quarters · filed 2020-02-25
$415.72M
10-K · filed 2021-02-11
2018-09-28$164.86M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30
$239.32M
derived: sum of 2 quarters · filed 2019-10-30
$311.13M
10-Q · filed 2019-10-30
$364.48M
derived: sum of 4 quarters · filed 2020-02-25
2018-06-29$74.47M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31
$146.27M
10-Q · filed 2019-07-31
$146.58M
10-Q · filed 2018-08-01
$199.63M
derived: sum of 3 quarters · filed 2020-02-25
$237.49M
derived: sum of 4 quarters · filed 2020-02-25
2018-03-30$71.81M
10-Q · filed 2019-05-01
$125.16M
derived: sum of 2 quarters · filed 2020-02-25
$163.03M
derived: sum of 3 quarters · filed 2020-02-25
2017-12-29$53.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$91.22M
derived: sum of 2 quarters · filed 2020-02-25
$165.61M
10-K · filed 2020-02-25
2017-09-30$37.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$112.26M
10-Q · filed 2017-11-01
2017-09-29$37.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$43.40M
derived: sum of 2 quarters · filed 2018-11-01
$112.26M
10-Q · filed 2018-11-01
$193.26M
derived: sum of 4 quarters · filed 2018-11-01
2017-06-30$5.54M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$74.39M
10-Q · filed 2017-08-02
$155.39M
derived: sum of 3 quarters · filed 2018-05-02
$149.61M
derived: sum of 4 quarters · filed 2018-05-02
2017-03-31$68.86M
10-Q · filed 2017-05-01
$149.86M
derived: sum of 2 quarters · filed 2018-05-02
$144.08M
derived: sum of 3 quarters · filed 2018-05-02
$118.34M
derived: sum of 4 quarters · filed 2018-05-02
2016-12-31$81.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$75.22M
derived: sum of 2 quarters · filed 2017-11-01
$49.49M
derived: sum of 3 quarters · filed 2017-11-01
$206.30M
10-K · filed 2017-02-27
2016-12-30$210.40M
10-K · filed 2019-02-22
2016-09-30-$5.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
-$31.52M
derived: sum of 2 quarters · filed 2017-11-01
$125.30M
10-Q · filed 2017-11-01
$122.58M
10-Q · filed 2016-11-03
$89.86M
derived: sum of 4 quarters · filed 2017-11-01
2016-06-30-$25.73M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02
$131.08M
10-Q · filed 2017-08-02
$129.02M
10-Q · filed 2016-08-03
$95.64M
derived: sum of 3 quarters · filed 2017-08-02
$61.41M
derived: sum of 4 quarters · filed 2017-08-02
2016-03-31$156.81M
10-Q · filed 2017-05-01
$154.90M
10-Q · filed 2016-05-04
$121.38M
derived: sum of 2 quarters · filed 2017-05-01
$87.14M
derived: sum of 3 quarters · filed 2017-05-01
$60.31M
derived: sum of 4 quarters · filed 2017-05-01
2016-01-01-$141.05M
10-K · filed 2018-02-26
2015-12-31-$35.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
-$69.67M
derived: sum of 2 quarters · filed 2017-02-27
-$96.50M
derived: sum of 3 quarters · filed 2017-02-27
-$141.59M
10-K · filed 2017-02-27
2015-09-30-$34.23M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03
-$61.07M
derived: sum of 2 quarters · filed 2016-11-03
-$106.15M
10-Q · filed 2016-11-03
-$156.13M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30-$26.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03
-$71.92M
10-Q · filed 2016-08-03
-$121.89M
derived: sum of 3 quarters · filed 2017-02-27
-$179.90M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31-$45.09M
10-Q · filed 2016-05-04
-$95.06M
derived: sum of 2 quarters · filed 2017-02-27
-$153.07M
derived: sum of 3 quarters · filed 2017-02-27
-$208.41M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31-$49.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
-$107.98M
derived: sum of 2 quarters · filed 2017-02-27
-$163.32M
derived: sum of 3 quarters · filed 2017-02-27
-$235.41M
10-K · filed 2017-02-27
2014-09-30-$58.01M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10
-$113.34M
derived: sum of 2 quarters · filed 2015-11-10
-$185.43M
10-Q · filed 2015-11-10
-$232.76M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$55.34M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11
-$127.42M
10-Q · filed 2015-08-11
-$174.75M
derived: sum of 3 quarters · filed 2016-02-29
-$231.75M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$72.09M
10-Q · filed 2015-04-30
-$119.42M
derived: sum of 2 quarters · filed 2016-02-29
-$176.41M
derived: sum of 3 quarters · filed 2016-02-29
-$216.44M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$47.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$104.32M
derived: sum of 2 quarters · filed 2016-02-29
-$144.36M
derived: sum of 3 quarters · filed 2016-02-29
-$198.77M
10-K · filed 2016-02-29
2013-09-30-$56.99M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04
-$97.03M
derived: sum of 2 quarters · filed 2014-11-04
-$151.44M
10-Q · filed 2014-11-04
-$190.18M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30-$40.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31
-$94.45M
10-Q · filed 2014-07-31
-$133.19M
derived: sum of 3 quarters · filed 2015-03-02
-$167.24M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31-$54.41M
10-Q · filed 2014-05-01
-$93.15M
derived: sum of 2 quarters · filed 2015-03-02
-$127.20M
derived: sum of 3 quarters · filed 2015-03-02
-$162.59M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31-$38.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$72.79M
derived: sum of 2 quarters · filed 2015-03-02
-$108.18M
derived: sum of 3 quarters · filed 2015-03-02
-$123.15M
10-K · filed 2015-03-02
2012-09-30-$34.05M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30
-$69.44M
derived: sum of 2 quarters · filed 2013-10-30
-$84.41M
10-Q · filed 2013-10-30
-$113.58M
derived: sum of 4 quarters · filed 2014-02-20
2012-06-30-$35.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06
-$50.36M
10-Q · filed 2013-08-06
-$79.53M
derived: sum of 3 quarters · filed 2014-02-20
-$122.80M
derived: sum of 4 quarters · filed 2014-02-20
2012-03-31-$14.97M
10-Q · filed 2013-05-07
-$44.14M
derived: sum of 2 quarters · filed 2014-02-20
-$87.41M
derived: sum of 3 quarters · filed 2014-02-20
-$130.92M
derived: sum of 4 quarters · filed 2014-02-20
2011-12-31-$29.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20
-$72.44M
derived: sum of 2 quarters · filed 2014-02-20
-$115.96M
derived: sum of 3 quarters · filed 2014-02-20
-$159.23M
10-K · filed 2014-02-20
2011-09-30-$43.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07
-$86.78M
derived: sum of 2 quarters · filed 2012-11-07
-$130.06M
10-Q · filed 2012-11-07
-$108.81M
derived: sum of 4 quarters · filed 2013-02-21
2011-06-30-$43.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02
-$86.79M
10-Q · filed 2012-08-02
-$65.54M
derived: sum of 3 quarters · filed 2013-02-21
-$109.36M
derived: sum of 4 quarters · filed 2013-02-21
2011-03-31-$43.28M
10-Q · filed 2012-05-03
-$22.02M
derived: sum of 2 quarters · filed 2013-02-21
-$65.85M
derived: sum of 3 quarters · filed 2013-02-21
2010-12-31$21.25M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21
-$22.57M
derived: sum of 2 quarters · filed 2013-02-21
-$101.05M
10-K · filed 2013-02-21
2010-09-30-$43.83M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27
-$122.30M
10-Q · filed 2011-10-27
2010-06-30-$78.47M
10-Q · filed 2011-08-04
2009-12-31-$14.59M
10-K · filed 2012-02-22

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78